

VISIT...

LANZAROTE
Caliente.COM

Is antagonism of $\alpha 3\beta 4$ nicotinic receptors a strategy to reduce morphine dependence?

Olga D. Taraschenko*, Vishal Panchal, Isabelle M. Maisonneuve, Stanley D. Glick

Center for Neuropharmacology and Neuroscience MC-136, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208, USA

Received 9 December 2004; received in revised form 28 February 2005; accepted 2 March 2005

Available online 14 April 2005

Abstract

18-Methoxycoronaridine, a synthetic iboga alkaloid congener, has been previously shown to attenuate several signs of morphine withdrawal in rats. The recently discovered action of 18-methoxycoronaridine to block $\alpha 3\beta 4$ nicotinic receptors may be responsible for this effect. To test this hypothesis the effects of non-selective $\alpha 3\beta 4$ receptor antagonists, dextromethorphan, mecamylamine, bupropion, and their combinations, were assessed on acute naltrexone-precipitated (1 mg/kg i.p.) morphine withdrawal in rats.

Dextromethorphan (5–40 mg/kg, s.c.), mecamylamine (0.25–4 mg/kg, i.p.) and bupropion (10–30 mg/kg, i.p.) alone produced variable effects on signs of withdrawal. However, two low-dose combinations, i.e., dextromethorphan (5 mg/kg, s.c.) and mecamylamine (0.25 mg/kg, i.p.), mecamylamine (0.25 mg/kg, i.p.) and bupropion (10 mg/kg, i.p.) as well as the three-drug combination significantly attenuated diarrhea and weight loss; none of the agents administered alone had these effects. The results of the present study provide evidence that $\alpha 3\beta 4$ nicotinic receptors are involved in the expression of at least two signs of opioid withdrawal.

© 2005 Elsevier B.V. All rights reserved.

Keywords: Morphine; Naltrexone; Dextromethorphan; Mecamylamine; Bupropion; Opioid withdrawal

1. Introduction

Opioid addiction is a major public health problem in the United States. The withdrawal syndrome in opioid-dependent humans is extremely unpleasant and is manifested as tachycardia, hypertension, sweating, diarrhea, vomiting, irritability and insomnia. The symptoms arise from the loss of chronic opioid inhibition of an up-regulated cAMP pathway in a subset of neurons in the central nervous system (locus coeruleus, nucleus accumbens) and in peripheral sites (gut) (Cami and Farre, 2003; Nestler and Aghajanian, 1997; Vetulani, 2001). The abstinence syndrome frequently appears as early as 4–6 h following discontinuation of short-acting opioids (which have the highest potential for abuse) and intensifies at 24–48 h, lasting up to 14 days. The avoidance of aversive abstinence symptoms serves as a

negative reinforcer that promotes drug seeking and drug taking. Despite a need for new agents designed to alleviate withdrawal symptoms, only a few treatments are currently available. The most commonly used treatment is based on cross-tolerance and involves administration of the long-acting opioid agonist methadone. This therapy is restricted to hospital use and specially licensed outpatient programs (Kosten and O'Connor, 2003; O'Brien, 2001). The second treatment option involves the use of an $\alpha 2$ -adrenoreceptor agonist clonidine, which reduces norepinephrine release from the locus coeruleus neurons by acting on inhibitory autoreceptors (Kosten and O'Connor, 2003; O'Brien, 2001). This treatment does not reduce opioid craving and is frequently associated with hypotension. A number of other agents are being tested in preclinical studies.

18-Methoxycoronaridine, a synthetic iboga alkaloid congener, is currently being studied for the treatment of drug addiction. Reports from this laboratory have shown that 18-methoxycoronaridine reduces the self-administration of morphine (Glick et al., 1996) and attenuates several signs

* Corresponding author. Tel.: +1 518 262 5849; fax: +1 518 262 5799.

E-mail address: tarasco@mail.amc.edu (O.D. Taraschenko).

of morphine withdrawal in rats (Rho and Glick, 1998). In the nucleus accumbens, pretreatment with 18-methoxycoronaridine abolishes the sensitized increase in dopamine levels induced by chronic morphine administration (Szumlinski et al., 2000). Until recently, the exact molecular mechanism mediating 18-methoxycoronaridine's effects on dopamine release and drug self-administration remained elusive. However, recent *in vitro* studies have shown that 18-methoxycoronaridine is a potent antagonist of $\alpha 3\beta 4$ nicotinic receptors ($IC_{50}=0.75\ \mu M$) (Glick et al., 2002). In addition, a combination of a low dose (i.e., ineffective alone) of 18-methoxycoronaridine with a low dose of other agents known to block $\alpha 3\beta 4$ nicotinic receptors reduced morphine self-administration (Glick et al., 2002). These results suggested that antagonism of $\alpha 3\beta 4$ nicotinic receptors can modulate drug-seeking behavior.

The $\alpha 3\beta 4$ nicotinic receptor antagonists referred to above included dextromethorphan ($IC_{50}=8.9\ \mu M$), mecamylamine ($IC_{50}=1\ \mu M$) and bupropion ($IC_{50}=1.5\text{--}1.8\ \mu M$) (Hernandez et al., 2000; Fryer and Lukas, 1999; Damaj et al., 2004). All three agents are currently available on the market and have been tried, with some success, for the treatment of different aspects of psychological and physical substance dependence. Thus, dextromethorphan, also an *N*-methyl-D-aspartate (NMDA) receptor antagonist and the active ingredient of anti-cough medications, has been shown to attenuate signs of opioid withdrawal in rodents and humans (Farzin, 1999; Koyuncuoglu et al., 1990; Koyuncuoglu and Saydam, 1990). However, the phencyclidine-like behavioral activation, present at high doses (Rosen et al., 1996), may limit clinical use of dextromethorphan. Mecamylamine, an antagonist of several nicotinic receptor subtypes, is about 3-fold more potent in blocking agonist-induced responses at $\alpha 3\beta 4$ neuronal nicotinic receptors than at $\alpha 4\beta 2$ and $\alpha 7$ receptors (Chavez-Noriega et al., 1997; Hernandez et al., 2000). Previously used as an antihypertensive, mecamylamine has been shown to be effective in reducing cue-induced craving in cocaine addicts (Reid et al., 1999) and in attenuating somatic stimulant effects of alcohol (Blomqvist et al., 2002; Chi and De Wit, 2003) and tobacco (Rose et al., 1994). Bupropion, widely used as an atypical antidepressant, is a dopamine transporter blocker, and is approved by the Food and Drug Administration for non-nicotine based therapy for smoking cessation (Glover and Glover, 2001; Hurt et al., 1997). Bupropion's therapeutic value for smoking cessation has been attributed to its blockade of nicotinic receptors (Fryer and Lukas, 1999). Thus, pharmacological blockade of central $\alpha 3$ -containing nicotinic receptors by bupropion and other drugs may play a significant role in drug dependence (Fryer and Lukas, 1999). The results indicating that $\alpha 3\beta 4$ nicotinic receptors mediate 18-methoxycoronaridine's effects on drug self-administration prompted us to assess whether $\alpha 3\beta 4$ nicotinic receptor antagonism might also be important for modulation of opioid withdrawal. To test this possibility we assessed the effects of dextromethorphan, mecamylamine

and bupropion, as well as low-dose combinations of these agents, in a rat model of acute opioid withdrawal.

2. Materials and methods

2.1. Drugs

Morphine sulfate and naltrexone hydrochloride (1 mg/kg) (Research Biochemicals Inc., Natick, MA) were dissolved in saline and injected subcutaneously and intraperitoneally, respectively. Dextromethorphan hydrobromide (5, 10, 20, 30 and 40 mg/kg, Sigma, St. Louis, MO) was dissolved in saline and injected subcutaneously. Mecamylamine hydrochloride (0.25, 0.5, 1, 2 and 4 mg/kg, Sigma) and bupropion hydrochloride (10, 20 and 30 mg/kg, Sigma) were dissolved in saline and injected intraperitoneally. For two-drug combinations the injection of dextromethorphan (0.5 mg/kg and 10 mg/kg) was immediately followed by an injection of mecamylamine (0.25 mg/kg and 0.5 mg/kg) or bupropion (10 mg/kg and 20 mg/kg); administration of mecamylamine (0.25 mg/kg and 0.5 mg/kg) was promptly followed by an injection of bupropion (10 mg/kg and 20 mg/kg). For the three-drug combination the injection of dextromethorphan (0.5 mg/kg, s.c.) was immediately followed by an injection of mecamylamine (0.25 mg/kg, i.p.) and bupropion (10 mg/kg, i.p.).

2.2. Animals

Naïve female Sprague–Dawley rats (Taconic, Germantown, NY), weighting 250–300 g, were housed individually and maintained on a normal 12:12-h light/dark cycle (light on at 7 a.m., light off at 7 p.m.). Food and water were provided *ad libitum*. All animal experiments were conducted in accordance with the "Guide for the Care and Use of Laboratory Animals" (National Academy of Sciences, 1996).

2.3. Morphine treatment

Morphine was administered subcutaneously twice a day (9.30 a.m. and 3.30 p.m.) for 7 days according to the following schedule: 10 and 20 mg/kg on the first day, 40 and 60 mg/kg on the second day, and 60 and 80 mg/kg on the third and subsequent days. This schedule was previously used by Rho and Glick (1998) to induce morphine dependence in rats.

2.4. Naltrexone-precipitated withdrawal

On the day of testing, pretreatment with either drug(s) or saline was followed 30 min later by injection of naltrexone. Signs of the precipitated withdrawal syndrome were observed and counted continuously for each 15-min interval for 2 h; the observations were made blindly. The following signs were monitored: "wet dog" shakes, rearing, grooming,

teeth chattering, burying, diarrhea. Rats were weighed twice: immediately prior to injection of naltrexone and 2 h later.

2.5. Data analysis

Withdrawal scores were expressed as percents of the appropriate control means and were analyzed with two-way analysis of variance (ANOVA) with dose and sign as the two factors. This analysis was followed by post hoc comparison tests (Fisher LSD). The analysis of time-course effects of the drugs was performed using repeated-measures ANOVA followed by post hoc comparison tests when appropriate.

3. Results

Naltrexone immediately precipitated a withdrawal syndrome in morphine-dependent rats which was characterized by “wet-dog” shaking, rearing, grooming, teeth chattering, burying, diarrhea and weight loss. The average withdrawal scores in all control saline-pretreated animals ($n=31$) were as follows (mean incidents per 2 h $\pm$ S.E.M., except for the weight loss in g): “wet-dog” shakes, 54.4 ± 5.3 ; rearing, 38.0 ± 4.9 ; grooming, 14.0 ± 1.4 ; teeth chattering, 21.2 ± 2.1 ; burying, 12.8 ± 1.6 ; diarrhea, 4.4 ± 0.3 ; and weight loss, 11.2 ± 0.5 . The mean scores for four out of six withdrawal signs (i.e., “wet-dog” shakes, rearing, burying and diarrhea) decreased while teeth chattering increased during the first hour. The mean score for grooming was unchanged during the 2-h period of observation.

3.1. Single-drug treatments

Mean withdrawal scores in control rats ($n=11$) for Figs. 1–3 were as follows (mean incidents per 2 h $\pm$ S.E.M.,

except for weight loss in g): “wet-dog” shakes, 60.1 ± 8.4 ; rearing, 50.6 ± 10.3 ; grooming, 13.8 ± 2.1 ; teeth chattering, 26.1 ± 4.5 ; burying, 13.5 ± 2.6 ; diarrhea, 3.5 ± 0.3 ; and weight loss, 10.4 ± 0.4 .

3.1.1. Dextromethorphan alone (Fig. 1)

Two-way ANOVA with dose of dextromethorphan and sign as the two factors revealed a significant main effect of treatment and a significant treatment $\times$ sign interaction [$F(5,33)=6.35$, $P<0.00031$ and $F(30,198)=2.27$, $P<0.0005$, respectively]. Further post hoc tests showed that three dosages of dextromethorphan (i.e., 5, 10 and 30 mg/kg) reduced the incidence of rearing, while two dosages (i.e., 30 and 40 mg/kg) reduced grooming. At 5 and 20 mg/kg dextromethorphan significantly attenuated and increased teeth chattering, respectively. The highest tested dose of dextromethorphan (i.e., 40 mg/kg) significantly attenuated burying. Dextromethorphan had no effect on “wet dog” shakes, diarrhea and weight loss.

3.1.2. Mecamylamine alone (Fig. 2)

Two-way ANOVA revealed a significant main effect of treatment and a significant treatment $\times$ sign interaction [$F(5,35)=7.56$, $P<0.00007$ and $F(30,210)=2.66$, $P<0.00003$, respectively]. Further post hoc tests showed that at 0.5 mg/kg and 1 mg/kg mecamylamine significantly increased “wet-dog” shakes. Three dosages (0.25, 0.5 and 2 mg/kg) reduced rearing, while two dosages (i.e., 0.5 and 2 mg/kg) attenuated teeth chattering. At 1 and 0.5 mg/kg mecamylamine significantly increased grooming and attenuated burying, respectively. All dosages except 0.25 mg/kg attenuated diarrhea, while three dosages (i.e., 0.5, 2 and 4 mg/kg) reduced weight loss.

3.1.3. Bupropion alone (Fig. 3)

The overall two-way ANOVA with dose of bupropion and sign as the two factors showed a significant main effect




Fig. 1. Effects of dextromethorphan on morphine withdrawal signs. Dextromethorphan or saline were administered 30 min before naltrexone (1 mg/kg, i.p.), and withdrawal signs (percent of control $\pm$ S.E.M.) were assessed for 2 h. * $P<0.05$, LSD test, dextromethorphan versus saline.




Fig. 2. Effects of mecamlamine on morphine withdrawal signs. Mecamlamine or saline were administered 30 min before naltrexone (1 mg/kg, i.p.) and withdrawal signs (percent of control $\pm$ S.E.M.) were assessed for 2 h. * $P < 0.05$, LSD test, mecamlamine versus saline.

of treatment and a significant treatment $\times$ sign interaction [$F(3,23) = 9.84$, $P < 0.00023$ and $F(18,138) = 2.53$, $P < 0.001$, respectively]. Bupropion (10 mg/kg) significantly attenuated rearing. At higher doses (i.e., 20 and 30 mg/kg) bupropion decreased grooming and burying while all dosages decreased teeth chattering. Bupropion had no effects on "wet-dog" shakes, diarrhea and weight loss.

3.2. Combination treatments

3.2.1. Dextromethorphan–mecamlamine combinations (Figs. 4–6)

Mean withdrawal scores in control rats ($n = 18$) were as follows (mean incidents per 2 h $\pm$ S.E.M., except for weight loss in g): "wet-dog" shakes, 66.9 ± 6.6 ; rearing, 42.9 ± 7.0 ; grooming, 13.6 ± 1.6 ; teeth chattering, 23.3 ± 3.07 ; burying, 11.0 ± 1.9 ; diarrhea, 3.6 ± 0.3 ; and weight loss, 11.0 ± 0.6 .

The effects of pretreatment with dextromethorphan (5 mg/kg, s.c.), mecamlamine (0.25 mg/kg, i.p.) and their combination are shown in Fig. 4. An overall two-way ANOVA with treatment and sign as the two factors revealed

a significant main effect of treatment ($F(3,34) = 9.72$, $P < 0.00009$). Post hoc tests showed that rearing and teeth chattering were significantly attenuated by each drug alone as well as their combination, while diarrhea and weight loss were attenuated by combination treatment only. The effects of combination were different from the effects of dextromethorphan alone for weight loss.

The effects of dextromethorphan (10 mg/kg), mecamlamine (0.5 mg/kg) and their combination are shown in Fig. 5. The overall two-way ANOVA showed a significant main effect of treatment and a significant treatment $\times$ sign interaction [$F(3,32) = 15.01$, $P < 0.00001$ and $F(18,192) = 3.34$, $P < 0.00002$, respectively].

Post hoc analysis showed that "wet-dog" shakes were significantly increased by dextromethorphan and mecamlamine alone but not by their combination; these effects of the individual drugs were also significantly different from the effect of their combination. The time-course of these effects is shown in Fig. 6. The overall repeated-measures ANOVA with treatment and time as the two factors revealed a significant main effect of the treatment and a significant treatment $\times$ time




Fig. 3. Effects of bupropion on morphine withdrawal signs. Bupropion or saline were administered 30 min before naltrexone (1 mg/kg, i.p.), and withdrawal signs (percent of control $\pm$ S.E.M.) were assessed for 2 h. * $P < 0.05$, LSD test, bupropion versus saline.




Fig. 4. Effects of the combination of dextromethorphan (5 mg/kg, s.c.) and mecamlamine (0.25 mg/kg, i.p.) on morphine withdrawal signs. Drug treatments or vehicle (saline) were administered 30 min before naltrexone (1 mg/kg, i.p.), and withdrawal signs (percent of control $\pm$ S.E.M.) were assessed for 2 h. * $P < 0.05$, LSD test, drug versus control; † $P < 0.05$, LSD test, individual drug versus drug combination.

interaction [$F(3,32) = 5.71$, $P < 0.003$ and $F(21,224) = 2.81$, $P < 0.00008$, respectively]. Further post hoc tests showed that dextromethorphan and mecamlamine alone significantly increased “wet-dog” shaking at all time points except 120 min after naltrexone. However, the combination of these agents significantly attenuated “wet-dog” shakes at 15 and 60–105 min after naltrexone. The effect of the combination was significantly different from the effect of each drug alone at all time points except 120 min. In contrast to the results for the combined 2-h means (Fig. 5), this analysis demonstrated that the combination treatment significantly attenuated wet-dog shaking at five out of eight time points after naltrexone.

Post hoc tests following the initial overall ANOVA showed that neither dextromethorphan or mecamlamine affected grooming, but their combination significantly attenuated it; the effect of the combination was also significantly different from that of mecamlamine alone (Fig. 5). Teeth chattering was significantly attenuated by

mecamlamine alone and by combination. For this sign the effects of combination were different from those of dextromethorphan alone (Fig. 5). Rearing was attenuated by either drug alone, but not by their combination while burying was reduced by mecamlamine only. Diarrhea and weight losses were significantly attenuated by mecamlamine alone and by combination. For those two signs the effects of combination were different from those of dextromethorphan alone.

3.2.2. Mecamlamine–bupropion combinations (Figs. 7 and 8)

Mean withdrawal scores in control rats ($n = 18$) were as follows (mean incidents per 2 h $\pm$ S.E.M., except for weight loss in g): “wet-dog” shakes, 52.3 ± 6.0 ; rearing, 42.9 ± 7.2 ; grooming, 12.8 ± 1.5 ; teeth chattering, 22.9 ± 3.0 ; burying, 14.9 ± 2.1 ; diarrhea, 3.8 ± 0.4 ; and weight loss, 10.6 ± 0.5 .

The effects of mecamlamine (0.25 mg/kg, i.p.), bupropion (10 mg/kg, i.p.) and their combination are shown in Fig.




Fig. 5. Effects of the combination of dextromethorphan (10 mg/kg, s.c.) and mecamlamine (0.5 mg/kg, i.p.) on morphine withdrawal signs. Drug treatments or vehicle (saline) were administered 30 min before naltrexone (1 mg/kg, i.p.), and withdrawal signs (percent of control $\pm$ S.E.M.) were assessed for 2 h. * $P < 0.05$, LSD test, drug versus control; † $P < 0.05$, LSD test, individual drug versus drug combination.




Fig. 6. Time-course of the effects of dextromethorphan (10 mg/kg, s.c., $n=6$), mecamlamine (0.5 mg/kg, i.p., $n=6$) and their combination ($n=6$) on "wet-dog" shakes. Drug treatments or vehicle (saline) were administered 30 min before naltrexone (1 mg/kg, i.p.), and signs of withdrawal (percent of control $\pm$ S.E.M.) were assessed for 2 h. * $P<0.05$, LSD test, drug versus control; † $P<0.05$, LSD test, individual drug versus drug combination.

7. An overall two-way ANOVA with treatment and sign as the two factors revealed a significant main effect of treatment and a significant treatment $\times$ sign interaction [$F(3,32)=5.37$, $P<0.004$ and $F(18,192)=2.86$, $P<0.0002$, respectively]. Post hoc tests revealed that rearing was significantly attenuated by either mecamlamine or bupropion, while grooming was increased by combination treatment. For these signs the effects of either drug alone were significantly different from the effects of combination. Teeth chattering was significantly attenuated by either drug alone and by their combination, while diarrhea and weight loss were reduced by combination treatment only. The effects of the combination treatment for diarrhea were also significantly different from those of the individual treatments. Neither treatment affected "wet-dog" shaking and burying.

The effects of mecamlamine (0.5 mg/kg, i.p.), bupropion (20 mg/kg, i.p.) and their combination are shown in Fig. 8. The overall two-way ANOVA demonstrated a significant main effect of treatment and a significant

treatment $\times$ sign interaction [$F(3,33)=11.12$, $P<0.00003$ and $F(18,198)=5.48$, $P<0.00001$, respectively]. Post hoc tests showed that "wet-dog" shaking was increased by mecamlamine and bupropion alone but not by their combination. Mecamlamine alone significantly attenuated rearing, while combination treatment increased this sign; the effect of mecamlamine for rearing was significantly different from that of the combination. Grooming was attenuated by bupropion only, while teeth chattering was reduced by both mecamlamine and bupropion; the combination treatment was not effective for those signs. The effect of bupropion on teeth chattering was also significantly different from that of combination. All three treatments (i.e., mecamlamine, bupropion and their combination) attenuated burying, while two treatments (i.e., mecamlamine and combination) attenuated diarrhea and weight loss. The effects of dextromethorphan on diarrhea and weight loss were also significantly different from those of their combination.




Fig. 7. Effect of the combination of mecamlamine (0.25 mg/kg, i.p.) and bupropion (10 mg/kg, i.p.) on morphine withdrawal signs. Drug treatments or vehicle (saline) were administered 30 min before naltrexone (1 mg/kg, i.p.) and withdrawal signs (percent of control $\pm$ S.E.M.) were assessed for 2 h. * $P<0.05$, LSD test, drug versus control; † $P<0.05$, LSD test, individual drug versus drug combination.




Fig. 8. Effects of the combination of mecamlamine (0.5 mg/kg, i.p.) and bupropion (20 mg/kg, i.p.) on morphine withdrawal signs. Drug treatments or vehicle (saline) were administered 30 min before naltrexone (1 mg/kg, i.p.) and withdrawal signs (percent of control $\pm$ S.E.M.) were assessed for 2 h. * P < 0.05, LSD test, drug versus control; † P < 0.05, LSD test, individual drug versus drug combination.

3.2.3. Dextromethorphan–bupropion combinations (Figs. 9 and 10)

Mean withdrawal scores in control rats ($n=18$) were as follows (mean incidents per 2 h $\pm$ S.E.M., except for weight loss in g): “wet-dog” shakes, 52.3 ± 6.0 ; rearing, 42.9 ± 7.2 ; grooming, 12.8 ± 1.5 ; teeth chattering, 22.9 ± 3.0 ; burying, 14.9 ± 2.1 ; diarrhea, 3.8 ± 0.4 ; and weight loss, 10.6 ± 0.5 .

The effects of dextromethorphan (5 mg/kg, s.c.), bupropion (10 mg/kg, i.p.) and their combination are shown in Fig. 9. The overall two-way ANOVA with treatment and sign as the two factors revealed a significant main effect of treatment and a significant treatment $\times$ sign interaction [$F(3,32)=4.77$, $P < 0.007$ and $F(18,192)=1.73$, $P < 0.04$, respectively]. Post hoc tests showed that dextromethorphan alone attenuated rearing although the combination treatment had no effect; the effects of either drug alone were also significantly different from that of the combination. Teeth chattering was reduced by both dextromethorphan and bupropion but not by their combination; the effect of

bupropion was also significantly different from that of combination. Burying was significantly reduced by bupropion alone and by the combination. Neither treatment had an effect on “wet-dog” shaking, diarrhea and weight loss.

The effects of dextromethorphan (10 mg/kg, s.c.), bupropion (20 mg/kg, i.p.) and their combination are shown in Fig. 10. The overall two-way ANOVA demonstrated a significant treatment $\times$ sign interaction ($F(18,198)=2.53$, $P < 0.001$). Post hoc analysis revealed that combination treatment significantly increased rearing, while only dextromethorphan alone was effective in reducing this sign. The effects of either drug alone were also significantly different from that of the combination. Grooming, teeth chattering and burying were significantly attenuated by bupropion only but not by the combination treatment. The effect of bupropion on teeth chattering was also significantly different from that of the combination. Neither treatment had an effect on “wet dog” shaking, grooming, diarrhea and weight loss.




Fig. 9. Effects of the combination of dextromethorphan (5 mg/kg, s.c.) and bupropion (10 mg/kg, i.p.) on morphine withdrawal signs. Drug treatments or vehicle (saline) were administered 30 min before naltrexone (1 mg/kg, i.p.), and withdrawal signs (percent of control $\pm$ S.E.M.) were assessed for 2 h. * P < 0.05, LSD test, drug versus control; † P < 0.05, LSD test, individual drug versus drug combination.




Fig. 10. Effects of the combination of dextromethorphan (10 mg/kg, s.c.) and bupropion (20 mg/kg, i.p.) on morphine withdrawal signs. Drug treatments or vehicle (saline) were administered 30 min before naltrexone (1 mg/kg, i.p.), and withdrawal signs (percent of control $\pm$ S.E.M.) were assessed for 2 h. * $P < 0.05$, LSD test, drug versus control; † $P < 0.05$, LSD test, individual drug versus drug combination.

3.2.4. Dextromethorphan–mecamylamine–bupropion combination (Fig. 11)

The effects of triple-agent combination treatment on diarrhea and weight loss are shown on Fig. 11. The mean withdrawal scores in control rats ($n = 17$) were as follows (mean incidents per 2 h $\pm$ S.E.M., except for weight loss in g): “wet-dog” shakes, 50.6 ± 7.4 ; rearing, 45.9 ± 7.8 ; grooming, 20.1 ± 4.6 ; teeth chattering, 23.4 ± 3.4 ; burying, 15.3 ± 2.5 ; diarrhea, 6.9 ± 1.7 ; and weight loss, 9.2 ± 0.5 .

The overall two-way ANOVA with treatment and sign as the two factors revealed a significant main effect of treatment and a significant treatment $\times$ sign interaction [$F(4,35) = 3.37$, $P < 0.02$] and $F(24,210) = 1.90$, $P < 0.001$, respectively]. Post hoc tests revealed that rearing was attenuated by either drug alone but not by their combination; the effects of individual drugs were also significantly different from those of the combination. Three drugs (i.e., dextromethorphan, mecamylamine and bupropion) signifi-

cantly reduced teeth chattering. The combination of three agents significantly attenuated grooming, diarrhea and weight loss, although none of the individual drugs had an effect. The effect of mecamylamine alone on all three signs was also significantly different from that of combination. Likewise, the effects of dextromethorphan and bupropion on weight loss were significantly different from those of combination.

4. Discussion

Nicotinic receptors may be important targets for novel medications for opioid dependence. 18-Methoxycoronaridine and dextromethorphan, both antagonists of $\alpha 3\beta 4$ nicotinic receptors, have previously been shown to reduce the expression of opioid withdrawal in animals and humans (Farzin, 1999; Koyuncuoglu et al., 1990; Koyuncuoglu and




Fig. 11. Effects of dextromethorphan (5 mg/kg, s.c.), mecamylamine (0.25 mg/kg, i.p.), bupropion (10 mg/kg, i.p.) and their combination on morphine withdrawal signs. Drug treatments or vehicle (saline, $n = 17$) were administered 30 min before naltrexone (1 mg/kg, i.p.). * $P < 0.05$, LSD test, drug versus control; † $P < 0.05$, LSD test, individual drug versus drug combination.

Saydam, 1990; Manning et al., 1996; Rho and Glick, 1998). In the present study, the effects of the non-selective $\alpha 3\beta 4$ nicotinic receptor antagonists dextromethorphan, mecamylamine, bupropion and their combinations were assessed on signs of acute naltrexone-precipitated opioid withdrawal in rats.

As expected, chronic morphine administration resulted in the development of opioid dependence such that injection of naltrexone precipitated acute withdrawal, characterized by the presence of the following signs: “wet-dog” shakes, rearing, grooming, teeth chattering, burying, diarrhea and weight loss. Consistent with previous work (Rasmussen and Vandergriff, 2003), the majority of withdrawal signs (i.e., “wet-dog” shakes, rearing, burying and diarrhea) were expressed maximally during the first 15 min after naltrexone, decreasing thereafter (data not shown). However, teeth chattering tended to increase over the first hour while grooming occurred at a constant rate during the first hour.

The opioid withdrawal syndrome has been linked to multiple brain sites and neurotransmitter systems. Rearing and teeth chattering have been associated with the overactivity of noradrenergic neurons in the nucleus locus coeruleus and periaqueductal gray (Maldonado et al., 1992). “Wet-dog” shakes have been attributed to the activation of the anterior hypothalamus and nucleus raphe magnus (Maldonado et al., 1992). The aversive motivational aspects of opiate withdrawal appear to involve the nucleus accumbens (Koob et al., 1992). The expression of somatic signs of opioid withdrawal in morphine-dependent rats does not correlate with the magnitude of withdrawal-induced aversion as measured with conditioned place preference (Hand et al., 1988; Mucha, 1987). The possible effects of $\alpha 3\beta 4$ antagonists and their combinations on motivational aspects of morphine withdrawal remain to be investigated.

Dextromethorphan, mecamylamine and bupropion each have unique actions (dextromethorphan blocks NMDA receptors, (Trujillo, 2000); mecamylamine blocks other subtypes of nicotinic receptors, (Papke et al., 2001); bupropion is an inhibitor of catecholamine uptake (Learned-Coughlin et al., 2003). However, the only action they have in common is to block nicotinic $\alpha 3\beta 4$ receptors (Fryer and Lukas, 1999; Hernandez et al., 2000; Papke et al., 2001). It was therefore reasoned that combinations of low doses of these agents would produce an additive effects at the common site (i.e., $\alpha 3\beta 4$ receptors) without producing effects mediated by their other actions. The results for only two out of seven signs of withdrawal, i.e., diarrhea and weight loss, were consistent with this premise. Thus, diarrhea and weight loss were attenuated by combinations of dextromethorphan and mecamylamine (5 mg/kg, s.c. and 0.25 mg/kg, i.p., respectively, Fig. 4), mecamylamine and bupropion (0.25 mg/kg, i.p. and 10 mg/kg, i.p., respectively, Fig. 7) as well as by the three-drug combination (Fig. 11). None of the agents administered alone had an

effect on these signs. Attenuation of diarrhea by the combined treatments in this study is likely mediated by actions of the drugs on both centrally and peripherally located $\alpha 3\beta 4$ nicotinic receptors. In the brain, $\alpha 3\beta 4$ receptors are present in the cerebellum, dorsal tegmentum, subiculum, anteroventral thalamic nucleus and the locus coeruleus (Perry et al., 2002; Whiteaker et al., 2002), although the highest densities of these receptors are in the nuclei of the habenulo–interpeduncular pathway (Mulle et al., 1991; Quick et al., 1999; Sheffield et al., 2000). The locus coeruleus is known to mediate the expression of diarrhea associated with morphine withdrawal (Taylor et al., 1988; Kimes et al., 1990) and may mediate attenuation of diarrhea produced by the combination treatments in this study. Furthermore, antagonists of $\alpha 3\beta 4$ nicotinic receptors could act in the dorsal motor nucleus of the vagus. This brain site expresses modest $\alpha 3\beta 4$ -like binding (Perry et al., 2002) and controls parasympathetic activity in the gastrointestinal tract. In the peripheral nervous system, $\alpha 3\beta 4$ nicotinic receptors are densely expressed in the myenteric neurons of the gut (Zhou et al., 2002). Nicotinic receptors containing $\alpha 3$ and $\beta 4$ subunits may mediate excitatory cholinergic neurotransmission in the gut and regulate intestinal peristalsis. Previous reports have shown that peristaltic contractions of murine ileal segments were attenuated by mecamylamine, a potent antagonist of myenteric $\alpha 3\beta 4$ nicotinic receptors ($IC_{50}=0.1 \mu M$) (Ren et al., 2003; Zhou et al., 2002). Thus, the attenuation of diarrhea and associated weight loss in the present study could be attributed to the action of the drugs at those peripheral receptor sites.

Antagonist-precipitated morphine withdrawal in rodents produces a variety of metabolic and endocrine effects that may induce weight loss. For example, opioid withdrawal in rats activates the hypothalamus–pituitary–adrenal axis via enhanced noradrenergic input, and causes an overproduction of corticotropin-releasing factor as well as an elevation of plasma corticosteroid levels (Gonzalez et al., 1994; Ignar and Kuhn, 1990; Milanese et al., 1998). Major noradrenergic afferents in the hypothalamus arrive from the hippocampus and brain stem nuclei that are enriched in $\alpha 3\beta 4$ nicotinic receptors. Therefore, by acting on those afferents, $\alpha 3\beta 4$ nicotinic antagonists could prevent activation of the hypothalamus during withdrawal and thus attenuate weight loss.

Consistent with an $\alpha 3\beta 4$ mechanism, grooming was attenuated by the higher-dose combination of dextromethorphan and mecamylamine (10 mg/kg, s.c. and 0.5 mg/kg, i.p., respectively, Fig. 5) as well as by the triple-drug combination (Fig. 11); the same doses of the individual drugs had no effect on grooming. The expression of grooming during withdrawal in morphine-dependent rats has been linked to the substantia nigra (Baumeister et al., 1992). Since this brain area does not express $\alpha 3\beta 4$ nicotinic receptors or expresses very low densities (Perry et al., 2002; Whiteaker et al., 2002), it

may have been affected indirectly. At the same time, although “wet-dog” shakes were significantly increased by either dextromethorphan (10 mg/kg, s.c.) or mecamlamine (0.5 mg/kg, i.p.) alone (Fig. 5), it was significantly attenuated by combination of those agents at 15 and 60–105 min after naltrexone (Fig. 6). The expression of “wet-dog” shakes during opioid withdrawal has been linked to the nucleus raphe magnus (Yap and Taylor, 1983), where there are moderate levels of $\alpha 3\beta 4$ nicotinic receptors (Perry et al., 2002).

The other effects produced by the individual drugs alone may have been due to their other actions. Previous studies have demonstrated that central glutamatergic mechanisms play an important role in the physiology of opioid withdrawal (for review, (Nestler and Aghajanian, 1997). The up-regulation of glutamate receptors is one of the neuro-adaptative processes associated with repeated opioid treatment. A variety of glutamatergic antagonists have been shown to attenuate opioid withdrawal (Farzin, 1999; Gonzalez et al., 1997; Herman et al., 1995; Manning et al., 1996; Popik and Skolnick, 1996). In previous studies, injection of dextromethorphan prior to naloxone treatment attenuated six signs of withdrawal in morphine-dependent mice (Farzin, 1999). Similarly, dextromethorphan reduced two out of eight signs of withdrawal in morphine-dependent rats (Koyuncuoglu et al., 1990). Such effects of dextromethorphan were attributed to the blockade of the effects of glutamate in brain sites responsible for the expression of withdrawal. The attenuation of rearing, grooming and burying by dextromethorphan alone in the present study were consistent with this mechanism (Fig. 1). Interestingly, 5 and 20 mg/kg of dextromethorphan significantly decreased and increased teeth chattering, respectively, whereas 30 and 40 mg/kg were ineffective. A biphasic dose-dependent effect of dextromethorphan on teeth chattering during opioid withdrawal was previously reported by Manning et al. (1996). The biphasic effect of dextromethorphan on rearing was also demonstrated in this study (Fig. 1). The mechanism of this effect remains unclear at this time.

Although mecamlamine has repeatedly been tested in nicotine and alcohol dependence paradigms (Blomqvist et al., 2002; Chi and De Wit, 2003; O'Dell et al., 2004; Rose et al., 1994), it has not previously been evaluated for opioid withdrawal. This drug may have promise for clinical use. While mecamlamine has affinity for the most prevalent nicotinic receptors in the brain, i.e., $\alpha 4\beta 2$ and $\alpha 7$ ($IC_{50}=2.5 \mu M$ and $6.9 \mu M$, respectively), it is most potent at the $\alpha 3\beta 4$ site ($IC_{50}=0.64 \mu M$) (Papke et al., 2001). The differential dose-dependent effects of mecamlamine alone in this study may be due to its actions on different nicotinic receptor subtypes.

Bupropion's effects were most probably mediated by its central actions (Suckow et al., 1986). In the brain bupropion is nearly equally potent at blocking $\alpha 3\beta 4$ nicotinic receptors and blocking dopamine and norepinephrine uptake (Damaj

et al., 2004). In the present study, when administered alone, bupropion significantly reduced several signs of withdrawal (i.e., rearing, grooming, teeth chattering and burying, Fig. 3). At the same time, the action of bupropion on dopamine uptake in certain brain areas may have dominated over its action on nicotinic receptors; thus, the increase in extracellular dopamine may have prevented the attenuation of some signs of withdrawal. For example, increased extracellular dopamine in the nucleus accumbens or medial prefrontal cortex has been associated with excessive rearing (Narita et al., 2003) and “wet-dog” shaking (Bassareo et al., 1995), respectively.

As discussed earlier, different signs of opioid withdrawal appear to be mediated by different neural systems. The results of the present study provide evidence that $\alpha 3\beta 4$ nicotinic receptors are involved in the expression of at least two signs of opioid withdrawal.

Acknowledgments

This research was supported by NIDA Grant DA 016283. Vishal Panchal was supported by an Alpha Omega Alpha Student Research Fellowship Award.

References

- Bassareo, V., Tanda, G., Di Chiara, G., 1995. Increase of extracellular dopamine in the medial prefrontal cortex during spontaneous and naloxone-precipitated opiate abstinence. *Psychopharmacology (Berl.)* 122, 202–205.
- Baumeister, A.A., Richard, A.L., Richmond-Landech, L., Hurry, M.J., Waguespack, A.M., 1992. Further studies of the role of opioid receptors in the nigra in the morphine withdrawal syndrome. *Neuropharmacology* 31, 835–841.
- Blomqvist, O., Hernandez-Avila, C.A., Van Kirk, J., Rose, J.E., Kranzler, H.R., 2002. Mecamlamine modifies the pharmacokinetics and reinforcing effects of alcohol. *Alcohol., Clin. Exp. Res.* 26, 326–331.
- Cami, J., Farre, M., 2003. Drug addiction. *N. Engl. J. Med.* 349, 975–986.
- Chavez-Noriega, L.E., Crona, J.H., Washburn, M.S., Urrutia, A., Elliott, K.J., Johnson, E.C., 1997. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in *Xenopus* oocytes. *J. Pharmacol. Exp. Ther.* 280, 346–356.
- Chi, H., De Wit, H., 2003. Mecamlamine attenuates the subjective stimulant-like effects of alcohol in social drinkers. *Alcohol., Clin. Exp. Res.* 27, 780–786.
- Damaj, M.I., Carroll, F.I., Eaton, J.B., Navarro, H.A., Blough, B.E., Mirza, S., Lukas, R.J., Martin, B.R., 2004. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. *Mol. Pharmacol.* 66, 675–682.
- Farzin, D., 1999. Modification of naloxone-induced withdrawal signs by dextromethorphan in morphine-dependent mice. *Eur. J. Pharmacol.* 377, 35–42.
- Fryer, J.D., Lukas, R.J., 1999. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. *J. Pharmacol. Exp. Ther.* 288, 88–92.
- Glick, S.D., Kuehne, M.E., Maisonneuve, I.M., Bandarage, U.K., Molinari, H.H., 1996. 18-Methoxycoronaridine, a non-toxic iboga alkaloid

- congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. *Brain Res.* 719, 29–35.
- Glick, S.D., Maisonneuve, I.M., Kitchen, B.A., Fleck, M.W., 2002. Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. *Eur. J. Pharmacol.* 438, 99–105.
- Glover, E.D., Glover, P.N., 2001. Pharmacologic treatments for the nicotine dependent smoker. *Am. J. Health Behav.* 25, 179–182.
- Gonzalez, P., Cabello, P., Germany, A., Norris, B., Contreras, E., 1997. Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists. *Eur. J. Pharmacol.* 332, 257–262.
- Gonzalez, M.L., Milanés, M.V., Martinez-Pinero, M.G., Marin, M.T., Vargas, M.L., 1994. Effects of intracerebroventricular clonidine on the hypothalamic noradrenaline and plasma corticosterone levels of opiate naive rats and after naloxone-induced withdrawal. *Brain Res.* 647, 199–203.
- Hand, T.H., Koob, G.F., Stinus, L., Le Moal, M., 1988. Aversive properties of opiate receptor blockade: evidence for exclusively central mediation in naive and morphine-dependent rats. *Brain Res.* 474, 364–368.
- Herman, B.H., Vocci, F., Bridge, P., 1995. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. *Neuropsychopharmacology* 13, 269–293.
- Hernandez, S.C., Bertolino, M., Xiao, Y., Pringle, K.E., Caruso, F.S., Kellar, K.J., 2000. Dextromethorphan and its metabolite dextrorphan block alpha3beta4 neuronal nicotinic receptors. *J. Pharmacol. Exp. Ther.* 293, 962–967.
- Hurt, R.D., Sachs, D.P., Glover, E.D., Offord, K.P., Johnston, J.A., Dale, L.C., Khayrallah, M.A., Schroeder, D.R., Glover, P.N., Sullivan, C.R., Croghan, I.T., Sullivan, P.M., 1997. A comparison of sustained-release bupropion and placebo for smoking cessation. *N. Engl. J. Med.* 337, 1195–1202.
- Ignar, D.M., Kuhn, C.M., 1990. Effects of specific mu and kappa opiate tolerance and abstinence on hypothalamo–pituitary–adrenal axis secretion in the rat. *J. Pharmacol. Exp. Ther.* 255, 1287–1295.
- Kimes, A.S., Bell, J.L., London, E.D., 1990. Clonidine attenuates increased brain metabolism during naloxone-precipitated morphine withdrawal. *Neuroscience* 34, 633–644.
- Koob, G.F., Maldonado, R., Stinus, L., 1992. Neural substrates of opiate withdrawal. *Trends Neurosci.* 15, 186–191.
- Kosten, T.R., O'Connor, P.G., 2003. Management of drug and alcohol withdrawal. *N. Engl. J. Med.* 348, 1786–1795.
- Koyuncuoglu, H., Saydam, B., 1990. The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chlorpromazine. *Int. J. Clin. Pharmacol. Ther. Toxicol.* 28, 147–152.
- Koyuncuoglu, H., Gungor, M., Sagduyu, H., Aricioglu, F., 1990. Suppression by ketamine and dextromethorphan of precipitated abstinence syndrome in rats. *Pharmacol. Biochem. Behav.* 35, 829–832.
- Learned-Coughlin, S.M., Bergstrom, M., Savitcheva, I., Ascher, J., Schmith, V.D., Langstrom, B., 2003. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. *Biol. Psychiatry* 54, 800–805.
- Maldonado, R., Stinus, L., Gold, L.H., Koob, G.F., 1992. Role of different brain structures in the expression of the physical morphine withdrawal syndrome. *J. Pharmacol. Exp. Ther.* 261, 669–677.
- Manning, B.H., Mao, J., Frenk, H., Price, D.D., Mayer, D.J., 1996. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. *Pain* 67, 79–88.
- Milanés, M.V., Laorden, M.L., Chapleur-Chateau, M., Burlet, A., 1998. Alterations in corticotropin-releasing factor and vasopressin content in rat brain during morphine withdrawal: correlation with hypothalamic noradrenergic activity and pituitary–adrenal response. *J. Pharmacol. Exp. Ther.* 285, 700–706.
- Mucha, R.F., 1987. Is the motivational effect of opiate withdrawal reflected by common somatic indices of precipitated withdrawal? A place conditioning study in the rat. *Brain Res.* 418, 214–220.
- Mulle, C., Vidal, C., Benoit, P., Changeux, J.P., 1991. Existence of different subtypes of nicotinic acetylcholine receptors in the rat habenulo–interpeduncular system. *J. Neurosci.* 11, 2588–2597.
- Narita, M., Takagi, M., Aoki, K., Kuzumaki, N., Suzuki, T., 2003. Implication of Rho-associated kinase in the elevation of extracellular dopamine levels and its related behaviors induced by methamphetamine in rats. *J. Neurochem.* 86, 273–282.
- Nestler, E.J., Aghajanian, G.K., 1997. Molecular and cellular basis of addiction. *Science* 278, 58–63.
- O'Brien, C.P., 2001. Drug addiction and drug abuse. In: Hardman, J.J., Limbird, E., Gilman, A.G. (Eds.), *The Pharmacological Basis of Therapeutics*, tenth ed. McGraw-Hill, pp. 621–642.
- O'Dell, L.E., Bruijnzeel, A.W., Ghosland, S., Markou, A., Koob, G.F., 2004. Nicotine withdrawal in adolescent and adult rats. *Ann. N.Y. Acad. Sci.* 1021, 167–174.
- Papke, R.L., Sanberg, P.R., Shytle, R.D., 2001. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. *J. Pharmacol. Exp. Ther.* 297, 646–656.
- Perry, D.C., Xiao, Y., Nguyen, H.N., Musachio, J.L., Davila-Garcia, M.I., Kellar, K.J., 2002. Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography. *J. Neurochem.* 82, 468–481.
- Popik, P., Skolnick, P., 1996. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. *Pharmacol. Biochem. Behav.* 53, 791–797.
- Quick, M.W., Ceballos, R.M., Kasten, M., McIntosh, J.M., Lester, R.A., 1999. Alpha3beta4 subunit-containing nicotinic receptors dominate function in rat medial habenula neurons. *Neuropharmacology* 38, 769–783.
- Rasmussen, K., Vandergriff, J., 2003. The selective iGluR1–4 (AMPA) antagonist LY300168 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioural signs of morphine withdrawal. *Neuropharmacology* 44, 88–92.
- Reid, M.S., Mickalian, J.D., Delucchi, K.L., Berger, S.P., 1999. A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects. *Neuropsychopharmacology* 20, 297–307.
- Ren, J., Bian, X., DeVries, M., Schnegelsberg, B., Cockayne, D.A., Ford, A.P., Galligan, J.J., 2003. P2X2 subunits contribute to fast synaptic excitation in myenteric neurons of the mouse small intestine. *J. Physiol.* 552, 809–821.
- Rho, B., Glick, S.D., 1998. Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats. *NeuroReport* 9, 1283–1285.
- Rose, J.E., Behm, F.M., Westman, E.C., Levin, E.D., Stein, R.M., Ripka, G.V., 1994. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. *Clin. Pharmacol. Ther.* 56, 86–99.
- Rosen, M.I., McMahon, T.J., Woods, S.W., Pearsall, H.R., Kosten, T.R., 1996. A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. *Eur. J. Pharmacol.* 307, 251–257.
- Sheffield, E.B., Quick, M.W., Lester, R.A., 2000. Nicotinic acetylcholine receptor subunit mRNA expression and channel function in medial habenula neurons. *Neuropharmacology* 39, 2591–2603.
- Suckow, R.F., Smith, T.M., Perumal, A.S., Cooper, T.B., 1986. Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs. *Drug Metab. Dispos.* 14, 692–697.
- Szumliński, K.K., Maisonneuve, I.M., Glick, S.D., 2000. The potential anti-addictive agent, 18-methoxycoronaridine, blocks the sensitized locomotor and dopamine responses produced by repeated morphine treatment. *Brain Res.* 864, 13–23.
- Taylor, J.R., Elsworth, J.D., Garcia, E.J., Grant, S.J., Roth, R.H., Redmond Jr., D.E., 1988. Clonidine infusions into the locus coeruleus attenuate behavioral and neurochemical changes associated with naloxone-precipitated withdrawal. *Psychopharmacology (Berl.)* 96, 121–134.
- Trujillo, K.A., 2000. Are NMDA receptors involved in opiate-induced neural and behavioral plasticity? A review of preclinical studies. *Psychopharmacology (Berl.)* 151, 121–141.

- Vetulani, J., 2001. Drug addiction: Part II. Neurobiology of addiction. *Pol. J. Pharmacol.* 53, 303–317.
- Whiteaker, P., Peterson, C.G., Xu, W., McIntosh, J.M., Paylor, R., Beaudet, A.L., Collins, A.C., Marks, M.J., 2002. Involvement of the alpha3 subunit in central nicotinic binding populations. *J. Neurosci.* 22, 2522–2529.
- Yap, C.Y., Taylor, D.A., 1983. Involvement of 5-HT₂ receptors in the wet-dog shake behavior induced by 5-hydroxytryptophan in the rat. *Neuropharmacology* 22, 801–804.
- Zhou, X., Ren, J., Brown, E., Schneider, D., Caraballo-Lopez, Y., Galligan, J.J., 2002. Pharmacological properties of nicotinic acetylcholine receptors expressed by guinea pig small intestinal myenteric neurons. *J. Pharmacol. Exp. Ther.* 302, 889–897.